Indegene has appointed Jill DeSimone to its Board of Directors.
DeSimone brings more than four decades of experience across the life sciences sector to Indegene’s Board. She has helped to build and scale multiple major companies and medical organisations. Previous roles held by DeSimone include President of US Oncology at Merck, Senior Vice President, US Oncology at Bristol Myers Squibb and Senior Vice President, Global Women’s Health at Teva. During her time at Merck, DeSimone led the launch of the oncology treatment Keytruda.
Since leaving Merck, DeSimone has served on the boards of a wide variety of biotechnology companies. These include Kinnate Biopharma, Oncternal Therapeutics, Affini-T Therapeutics, iTeos Therapeutics and Praxis Precision Medicines. She is also a Consulting Advisor at her own independent consulting firm, JM DeSimone Consulting, where she provides strategic advice to pre-clinical and early-stage companies in the life sciences sector.
The appointment of DeSimone to Indegene’s Board will help to drive Indegene’s ongoing growth as it assists its life sciences clients in commercialisation and execution.
DeSimone said: “Life sciences organisations are navigating increasing scientific complexity and higher expectations across the product life cycle. Indegene’s practitioner-led, technology-enabled approach positions it well to support this evolution.”